Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens on Phase 2 Data
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $155.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
